NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum
October 26 2022 - 6:50AM
Business Wire
New super-charged serum helps men and women
minimize the size of enlarged facial pores
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the newest addition to the DERMAdoctor® Picture Porefect®
collection: 15% Niacinamide Pore Minimizing Serum. This new,
high-potency formulation minimizes the size of visible facial pores
while delivering free-radical-neutralizing antioxidants and
collagen-supporting agents to reduce blackheads, skin
discoloration, rough skin, acne, and oily or combination skin.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221026005007/en/
DERMAdoctor Picture Porefect 15%
Niacinamide Pore Minimizing Serum (Photo: Business Wire)
“The appearance of enlarged pores is a concern of many women who
strive to achieve their most beautiful complexion,” said NovaBay
Chief Product Officer Audrey Kunin, MD, a board-certified
dermatologist. “Our new supercharged 15% Niacinamide Pore
Minimizing Serum helps neutralize the effects of environmental
stressors such as sunlight, pollution and toxins, leaving skin
looking and feeling radiant. Gentler than retinol,
niacinamide-based products can be used daily. In fact, just five
drops of this highly concentrated serum on clean, dry facial skin
twice a day can achieve a complexion free of large or congested
pores, redness and skin discoloration, with or without makeup.”
Picture Porefect 15% Niacinamide Pore Minimizing Serum is
formulated with proven dermatological ingredients including the
antioxidant niacinamide (a form of vitamin B3) to help detoxify and
cleanse pores and reduce inflammation, vitamin C to support the
dermal collagen that keeps pores tight, zinc to help clarify
pore-plugging skin oils, and peptides to help dermal collagen
tighten pores and improve the appearance of fine lines and
wrinkles. The serum is now available in a 1 fluid ounce pump bottle
on Amazon.com and DERMAdoctor.com for $42.
All DERMAdoctor products are scientifically formulated to
provide measurable results for common skincare concerns that have
been largely overlooked by the beauty industry and are
hypoallergenic, non-irritating, non-drying, pH balanced and free of
synthetic fragrance and dye. DERMAdoctor sells its products through
major retailers such as Macy’s, QVC, Target.com and Costco.com, as
well as through digital beauty retailers including SkinStore,
Amazon.com and DERMAdoctor.com. DERMAdoctor products are also
available internationally through select distributors and
retailers.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
eyecare and skincare products. Avenova® is the most prescribed
antimicrobial lid and lash spray and DERMAdoctor® is a premium
skincare brand offering more than 30 dermatologist-developed
skincare products sold through traditional domestic retailers,
digital beauty channels and international distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including, but not limited to, statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding current and future product
offerings, marketing efforts, and any future revenue that may
result from selling such products, as well as generally the
Company’s expected future financial results (and ability to
continue as a going concern) and the impact of a reverse stock
split. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those
expressed in or implied by the forward-looking statements. New
risks and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. Other risks
relating to NovaBay’s business, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the SEC, especially under
the heading “Risk Factors,” and in the Preliminary Proxy Statement
filed by NovaBay with the SEC, especially under the heading
“Proposal Two: The Reverse Stock Split Proposal — Risks Relating to
the Reverse Stock Split.” The forward-looking statements in this
press release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook Follow us on Twitter Connect with NovaBay on
LinkedIn Visit NovaBay’s Website
Avenova Purchasing Information For NovaBay Avenova
purchasing information: Please call 800-890-0329 or email
sales@avenova.com Avenova.com
DERMAdoctor Purchasing Information For DERMAdoctor
purchasing information: Please call 877-337-6237 or email
service@dermadoctor.com DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221026005007/en/
NovaBay Contact Justin Hall Chief Executive Officer and
General Counsel 510-899-8800 jhall@novabay.com
Investor Contact LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024